Characteristics, risk factors and outcomes of adult cancer patients with extensively drug-resistant Pseudomonas aeruginosa infections

被引:45
|
作者
Samonis, G. [1 ]
Vardakas, K. Z. [2 ,3 ]
Kofteridis, D. P. [1 ]
Dimopoulou, D. [1 ]
Andrianaki, A. M. [1 ]
Chatzinikolaou, I. [4 ]
Katsanevaki, E. [5 ]
Maraki, S. [6 ]
Falagas, M. E. [2 ,3 ,7 ]
机构
[1] Univ Crete, Sch Med, Dept Internal Med, Iraklion, Greece
[2] Alfa Inst Biomed Sci, Athens 15123, Greece
[3] Iaso Gen Hosp, Dept Internal Med Infect Dis, Athens, Greece
[4] Metropolitan Gen Hosp, Dept Clin Oncol, Athens, Greece
[5] Natl Tech Univ Athens, Dept Appl Math & Phys, Athens, Greece
[6] Univ Hosp Heraklion, Dept Clin Microbiol, Iraklion, Crete, Greece
[7] Tufts Univ, Sch Med, Dept Internal Med, Boston, MA 02111 USA
关键词
Bacteremia; Pneumonia; Malignancy; Gram negative; Appropriate empirical treatment; Neutropenia; COMBINATION ANTIBIOTIC-THERAPY; BETA-LACTAM MONOTHERAPY; GRAM-NEGATIVE BACTERIA; BLOOD-STREAM INFECTION; INTENSIVE-CARE-UNIT; ACINETOBACTER-BAUMANNII; SEPTIC SHOCK; METAANALYSIS; AMINOGLYCOSIDE; COLISTIN;
D O I
10.1007/s15010-014-0635-z
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
To evaluate the characteristics and outcomes of cancer patients with extensively drug-resistant (XDR) Pseudomonas aeruginosa infections. This was a retrospective cohort of P. aeruginosa infections in cancer patients in Crete, Greece. Patients were followed until discharge. Mortality, predictors of mortality and risk factors for XDR P. aeruginosa infection were studied. Ninety seven episodes (89 patients) of P. aeruginosa infections (52 with bacteremia) were included in the study. In 22 cases, the infection was due to XDR isolates. All XDR isolates were susceptible to colistin and variably resistant to almost all other antibiotics. The multivariate analysis showed that the independent risk factors for XDR P. aeruginosa infection were hematologic malignancy (OR 40.7, 95 % CI 4.5-367.6) and prior fluoroquinolone use (OR 11.0, 95 % CI 2.0-60.5); lymphopenia was inversely associated with XDR infections (OR 0.16, 95 % CI 0.03-0.92). Mortality was 43 %; infection-related mortality was 24 %. Bacteremia (OR 8.47, 95 % CI 2.38-30.15), infection due to XDR isolates (OR 5.11, 95 % CI 1.15-22.62) and age (OR 1.05, 95 % CI 1.00-1.09) were independently associated with mortality. Mortality in cancer patients with P. aeruginosa infections was high. Infection due to XDR isolates was independently associated with mortality.
引用
收藏
页码:721 / 728
页数:8
相关论文
共 50 条
  • [41] Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain
    del Barrio-Tofino, Ester
    Lopez-Causape, Carla
    Cabot, Gabriel
    Rivera, Alba
    Benito, Natividad
    Segura, Concepcion
    Milagro Montero, Maria
    Sorli, Luisa
    Tubau, Fe
    Gomez-Zorrilla, Silvia
    Tormo, Nuria
    Dura-Navarro, Raquel
    Viedma, Esther
    Resino-Foz, Elena
    Fernandez-Martinez, Marta
    Gonzalez-Rico, Claudia
    Alejo-Cancho, Izaskun
    Antonio Martinez, Jose
    Labayru-Echverria, Cristina
    Duenas, Carlos
    Ayestaran, Ignacio
    Zamorano, Laura
    Martinez-Martinez, Luis
    Pablo Horcajada, Juan
    Oliver, Antonio
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (11)
  • [42] Draft Genome Sequence of a Clinically Isolated Extensively Drug-Resistant Pseudomonas aeruginosa Strain
    Manivannan, Bhavani
    Mahalingam, Niranjana
    Jadhao, Sudhir
    Mishra, Amrita
    Nilawe, Pravin
    Pradeep, Bulagonda Eswarappa
    GENOME ANNOUNCEMENTS, 2016, 4 (02)
  • [43] Characterization and genetic analysis of extensively drug-resistant hospital acquired Pseudomonas aeruginosa isolates
    Abdelaziz, Mai A.
    El-Aziz, Abeer M. Abd
    El-Sokkary, Mohamed M. A.
    Barwa, Rasha
    BMC MICROBIOLOGY, 2024, 24 (01):
  • [44] Risk factors for extensively drug-resistant tuberculosis: a systematic review
    Lima, B. F.
    Tavares, M.
    Barros, H.
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2010, 15 : 110 - 110
  • [45] Impact of Ceftolozane–Tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Lower Respiratory Tract Infections
    Dana J. Holger
    Nicholas S. Rebold
    Sara Alosaimy
    Taylor Morrisette
    Abdalhamid Lagnf
    Ana Christine Belza
    Ashlan J. Kunz Coyne
    Amer El Ghali
    Michael P. Veve
    Michael J. Rybak
    Infectious Diseases and Therapy, 2022, 11 : 1965 - 1980
  • [46] Extensively and pan-drug resistant Pseudomonas aeruginosa keratitis: clinical features, risk factors, and outcome
    Fernandes, Merle
    Vira, Divya
    Medikonda, Radhika
    Kumar, Nagendra
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2016, 254 (02) : 315 - 322
  • [47] Extensively and pan-drug resistant Pseudomonas aeruginosa keratitis: clinical features, risk factors, and outcome
    Merle Fernandes
    Divya Vira
    Radhika Medikonda
    Nagendra Kumar
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2016, 254 : 315 - 322
  • [48] Acquisition of extensive drug-resistant Pseudomonas aeruginosa among hospitalized patients: risk factors and resistance mechanisms to carbapenems
    Park, Y. S.
    Lee, H.
    Chin, B. S.
    Han, S. H.
    Hong, S. G.
    Hong, S. K.
    Kim, H. Y.
    Uh, Y.
    Shin, H. B.
    Choo, E. J.
    Han, S. -H.
    Song, W.
    Jeong, S. H.
    Lee, K.
    Kim, J. M.
    JOURNAL OF HOSPITAL INFECTION, 2011, 79 (01) : 54 - 58
  • [49] Phage therapy to allow liver transplantation in a toddler infected by an extensively drug-resistant Pseudomonas aeruginosa
    Van Nieuwenhuyse, Brieuc
    Van der Linden, Dimitri
    Chatzis, Olga
    Lood, Cedric
    Wagemans, Jeroen
    Lavigne, Rob
    de Magnee, Catherine
    Sokal, Etienne
    Rodriguez-Villalobos, Hector
    Djebara, Sarah
    Merabishvili, Maya
    Soentjens, Patrick
    Pirnay, Jean-Paul
    PEDIATRIC TRANSPLANTATION, 2022, 26
  • [50] Tazobactam/ceftolozane and tobramycin combination therapy in extensively drug-resistant Pseudomonas aeruginosa infections in severe burn injury: a case report
    Yuta Ibe
    Ryuichiro Kakizaki
    Hirotoshi Inamura
    Tomoyuki Ishigo
    Yoshihiro Fujiya
    Hiroyuki Inoue
    Shuji Uemura
    Satoshi Fujii
    Satoshi Takahashi
    Eichi Narimatsu
    Masahide Fukudo
    Journal of Pharmaceutical Health Care and Sciences, 9